Alembic Pharmaceuticals announces USFDA Final Approval for Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg

Friday January 22, 2021 at 12:40 pm

Alembic Pharmaceuticals Limited (Alembic) today announced it has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), ProAmatine Tablets, 2.5 mg, 5 mg, and 10 mg, of Takeda Pharmaceuticals USA, Inc. (Takeda). Midodrine Hydrochloride Tablets are indicated for the treatment of symptomatic orthostatic hypotension (OH). Midodrine Hydrochloride Tablets USP 2.5 mg, 5 mg, and 10 mg have an estimated. the market size of US$ 60 million for twelve months ending September 2020 according to IQVIA. Alembic has a cumulative total of 138 ANDA approvals (120 final approvals and 18 tentative approvals) from USFDA.

Releted Blog
  • 5 Tips to Healthy Your Gut This Summer Season

    5 Tips to Healthy Your Gut This Summer Season Summer time can be a very stressful time for the gut and the gut has a lot of things to handle during...

  • Red beet juice good for you?

    Is red beet juice good for you? Red beet juice is it really good, isn't it? The nutrient-rich and vivid red beet juice is a very tempting choice fo...

  • Summer Season: Avoid These 5 Foods to Stay Healthy!

    During the summer, the air is usually hot and the body is producing more sweat which is why is it so important to stay hydrated. In addition to drinki...